RxDoctor Payments Data

Rommel Gonzales, MD

Family Medicine · Los Angeles, CANPI 1386998227

Payments from drug & device makers

$525in general payments, 2019–2025

Across 15 payments — averaging $35.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Shire North American Group Inc$240
  • Amgen$64
  • Novo Nordisk$50
  • Novartis$44
  • Sumitomo Pharma America, Inc.$37
  • Gilead$33
  • plus $57 from 3 others

What the payments were for

  • Consulting fees$24046%
  • Food & beverage$28554%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$525 in reported general payments places this provider in the 60th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$32,569
Medicare patients
122
Services billed
824

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate57$65,702
BiktarvyBictegrav/Emtricit/Tenofov Ala17$62,196
JardianceEmpagliflozin52$36,011
EliquisApixaban41$33,304
OzempicSemaglutide26$22,736
TrulicityDulaglutide11$16,746
EntrestoSacubitril/Valsartan11$15,990
RybelsusSemaglutide11$11,081
XareltoRivaroxaban13$9,692
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog28$5,699
Atorvastatin Calcium261$3,487
Tamsulosin Hcl124$2,615
Diclofenac Sodium77$2,327
Lantus SolostarInsulin Glargine,hum.Rec.Anlog20$2,061
Omeprazole149$2,021

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy$33$62,19617 claims
Novo NordiskOzempic, Rybelsus$50$33,81737 claims
Lilly USA, LLCTrulicity, Humulin 70-30$14$18,57926 claims
NovartisEntresto$44$15,99011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 10,533 family medicine providers in California.

Other family medicine in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →